Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.
about
Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptionsThe evolution of poxvirus vaccinesCurrent progress in the development of therapeutic vaccines for chronic hepatitis B virus infectionIn Silico Analysis of Epitope-Based Vaccine Candidates against Hepatitis B Virus Polymerase Protein.Identification of HBsAg-specific antibodies from a mammalian cell displayed full-length human antibody library of healthy immunized donorRegression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.An autophagosome-based therapeutic vaccine for HBV infection: a preclinical evaluation.A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.Mesenchymal stem cells as a novel vaccine platform.Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.Design of therapeutic vaccines: hepatitis B as an example.Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospectsTreatment of children with chronic viral hepatitis: what is available and what is in store.Clinical applications of attenuated MVA poxvirus strain.Treatment options beyond IFNα and NUCs for chronic HBV infection: expectations for tomorrow.Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end?Therapeutic vaccines in HBV: lessons from HCV.Developments in Viral Vector-Based Vaccines.Hepatitis B immunopathogenesis and immunotherapy.Microneedle-mediated delivery of viral vectored vaccines.Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes.Drugs in Development for Hepatitis B.Inhibition of HBV replication by VPS4B and its dominant negative mutant VPS4B-K180Q in vivo.
P2860
Q26777442-836DCCCA-2A70-443F-84CA-B9AC648F451EQ26995905-7A025607-1326-4C0A-A807-EE7FA10F0641Q28076279-B737DEBC-5BC9-4F84-ADD7-F2D0B595976DQ33753964-8CC8B375-2D92-4AEB-BF82-3D1CB021713CQ34104779-C4A85D7B-33D5-4D19-BDD4-386CA8242D82Q34729962-531AB9BD-0950-424A-8572-45D72085C3C3Q34995374-156A4AB2-256A-4E67-99ED-8C53033F5B67Q36391900-F5780AEB-9638-46FB-AB64-B06751A9DF18Q36404011-D043FCAA-1B61-43ED-92DF-D0DE465C9FA0Q36849770-88F3E63C-D0AF-46B5-9679-C849AB03D539Q37274697-060B301C-386F-495D-B949-089942E0F583Q37286061-D452BEF5-962A-43F6-B577-8382BB14F2E3Q38127616-E7C50068-DD80-497B-8D88-CE5D07EDB70BQ38156198-3E57378F-969A-49CE-B433-F5A0488ED566Q38255840-4952A0FE-0EA1-401A-9430-BC0C98DCDFE3Q38289734-631DAEC2-6D1D-43F2-BB18-DCC5F552D773Q38312255-AF3E6C9F-3935-477F-9BC0-B3BE3F6AB4EAQ38582090-34C2B1AD-ED35-4905-A39E-7FCFA180322BQ38773364-7F347806-F248-4BB6-97C6-87EF840DFEA5Q40596089-725A6604-40F3-4C05-A6E5-10D8D0B57E80Q42236065-4150DCC5-D8A4-433D-8673-6C04862EFEA4Q45325213-A176540E-57B8-4BB6-9DE1-19791F000066Q46773926-F705A6EE-6DB5-494E-9729-0874BF7A71B6Q52764230-1EABD45C-C0BA-48B1-8B0E-7B9E073FE13BQ55056246-BD31DFDD-B294-4FBD-A42A-DA266EA65753
P2860
Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Partially randomized, non-blin ...... tein for chronic HBV infection
@nl
Partially randomized, non-blin ...... ein for chronic HBV infection.
@ast
Partially randomized, non-blin ...... ein for chronic HBV infection.
@en
type
label
Partially randomized, non-blin ...... tein for chronic HBV infection
@nl
Partially randomized, non-blin ...... ein for chronic HBV infection.
@ast
Partially randomized, non-blin ...... ein for chronic HBV infection.
@en
prefLabel
Partially randomized, non-blin ...... tein for chronic HBV infection
@nl
Partially randomized, non-blin ...... ein for chronic HBV infection.
@ast
Partially randomized, non-blin ...... ein for chronic HBV infection.
@en
P2093
P2860
P1433
P1476
Partially randomized, non-blin ...... ein for chronic HBV infection.
@en
P2093
Hilton Whittle
James S Cavenaugh
Maimuna Mendy
P2860
P304
P356
10.1371/JOURNAL.PONE.0014626
P407
P577
2011-02-15T00:00:00Z